{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:18:44Z","timestamp":1793495924312,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41440-018-0116-3","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T23:10:31Z","timestamp":1554419431000},"page":"469-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1038","volume":"42","author":[{"given":"Eikan","family":"Mishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshisuke","family":"Haruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatomi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"116_CR1","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238\u201352.","journal-title":"Lancet"},{"key":"116_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","volume":"55","author":"P Muntner","year":"2010","unstructured":"Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Chronic Renal Insufficiency Cohort Study I. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441\u201351.","journal-title":"Am J Kidney Dis"},{"key":"116_CR3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","volume":"385","author":"SC Palmer","year":"2015","unstructured":"Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047\u201356.","journal-title":"Lancet"},{"key":"116_CR4","doi-asserted-by":"crossref","unstructured":"Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006:CD006257.","DOI":"10.1002\/14651858.CD006257"},{"key":"116_CR5","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1681\/ASN.2006101081","volume":"18","author":"DM Kent","year":"2007","unstructured":"Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18:1959\u201365.","journal-title":"J Am Soc Nephrol"},{"key":"116_CR6","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension . 2018;71:e13\u2013115.","journal-title":"Hypertension"},{"key":"116_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cjca.2018.02.022","volume":"34","author":"KA Nerenberg","year":"2018","unstructured":"Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada\u2019s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018;34:506\u201325.","journal-title":"Can J Cardiol"},{"key":"116_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ki.2012.425","volume":"83","author":"DC Wheeler","year":"2013","unstructured":"Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int. 2013;83:377\u201383.","journal-title":"Kidney Int"},{"key":"116_CR9","doi-asserted-by":"crossref","unstructured":"Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011:CD007751.","DOI":"10.1002\/14651858.CD007751.pub2"},{"key":"116_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"116_CR11","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65\u201394.","journal-title":"Ann Intern Med"},{"key":"116_CR12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089\u2013100.","journal-title":"Kidney Int"},{"key":"116_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939\u201345.","journal-title":"N Engl J Med"},{"key":"116_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359\u201364.","journal-title":"Lancet"},{"key":"116_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857\u201363.","journal-title":"Lancet"},{"key":"116_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131\u201340.","journal-title":"N Engl J Med"},{"key":"116_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751\u201360.","journal-title":"Am J Kidney Dis"},{"key":"116_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","volume":"5","author":"AL Kamper","year":"1992","unstructured":"Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens. 1992;5:423\u201330.","journal-title":"Am J Hypertens"},{"key":"116_CR19","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00432.x","volume":"58","author":"KT Woo","year":"2000","unstructured":"Woo KT, Lau YK, Wong KS, Chiang GS. ACEI\/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int. 2000;58:2485\u201391.","journal-title":"Kidney Int"},{"key":"116_CR20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ndt\/16.5.961","volume":"16","author":"GA Cinotti","year":"2001","unstructured":"Cinotti GA, Zucchelli PC. Collaborative Study G. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant. 2001;16:961\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.jhh.1002264","volume":"22","author":"T Mimura","year":"2008","unstructured":"Mimura T, Takenaka T, Kanno Y, Moriwaki K, Okada H, Suzuki H. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hypertens. 2008;22:38\u201347.","journal-title":"J Hum Hypertens"},{"key":"116_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/ki.1992.309","volume":"42","author":"P Zucchelli","year":"1992","unstructured":"Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452\u20138.","journal-title":"Kidney Int"},{"key":"116_CR23","first-page":"375","volume":"55","author":"LJ Petersen","year":"2001","unstructured":"Petersen LJ, Petersen JR, Talleruphuus U, Moller ML, Ladefoged SD, Mehlsen J, et al. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Clin Nephrol. 2001;55:375\u201383.","journal-title":"Clin Nephrol"},{"key":"116_CR24","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719\u201328.","journal-title":"JAMA"},{"key":"116_CR25","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/00004872-200110000-00023","volume":"19","author":"R Marin","year":"2001","unstructured":"Marin R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J. Investigators of the ESEdtaSlPdlIRepnd. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens. 2001;19:1871\u20136.","journal-title":"J Hypertens"},{"key":"116_CR26","doi-asserted-by":"publisher","first-page":"c139","DOI":"10.1159\/000086714","volume":"101","author":"MS MacGregor","year":"2005","unstructured":"MacGregor MS, Deighan CJ, Rodger RS, Boulton-Jones JM. A prospective open-label randomised trial of quinapril and\/or amlodipine in progressive non-diabetic renal failure. Nephron Clin Pract. 2005;101:c139\u201349.","journal-title":"Nephron Clin Pract"},{"key":"116_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.clinthera.2008.03.006","volume":"30","author":"VL Esnault","year":"2008","unstructured":"Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, et al. Amlodipine Versus Enalapril in Renal failure Study G. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2008;30:482\u201398.","journal-title":"Clin Ther"},{"key":"116_CR28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","volume":"309","author":"T Hannedouche","year":"1994","unstructured":"Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833\u20137.","journal-title":"BMJ"},{"key":"116_CR29","first-page":"S58","volume":"63","author":"GG Essen van","year":"1997","unstructured":"van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl. 1997;63:S58\u201362.","journal-title":"Kidney Int Suppl"},{"key":"116_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1440-1797.1998.d01-12.x","volume":"4","author":"IKP Cheng","year":"1998","unstructured":"Cheng IKP, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HWD. A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology. 1998;4:19\u201326.","journal-title":"Nephrology"},{"key":"116_CR31","doi-asserted-by":"publisher","first-page":"c18","DOI":"10.1159\/000081790","volume":"99","author":"K Nutahara","year":"2005","unstructured":"Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99:c18\u201323.","journal-title":"Nephron Clin Pract"},{"key":"116_CR32","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","volume":"18","author":"MA Dijk van","year":"2003","unstructured":"van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2003;18:2314\u201320.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/ndt\/gfm731","volume":"23","author":"R Zeltner","year":"2008","unstructured":"Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2008;23:573\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR34","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr.","year":"2002","unstructured":"Wright JT,Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. African American Study of Kidney D, Hypertension Study G. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421\u201331.","journal-title":"JAMA"},{"key":"116_CR35","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/archinte.165.8.936","volume":"165","author":"M Rahman","year":"2005","unstructured":"Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Charleston J, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936\u201346.","journal-title":"Arch Intern Med"},{"key":"116_CR36","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/ndt\/gfg284","volume":"18","author":"M Praga","year":"2003","unstructured":"Praga M, Andrade CF, Luno J, Arias M, Poveda R, Mora J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant. 2003;18:1806\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1291\/hypres.27.21","volume":"27","author":"Y Iino","year":"2004","unstructured":"Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, et al. Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients Study I. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27:21\u201330.","journal-title":"Hypertens Res"},{"key":"116_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/00004872-200204000-00032","volume":"20","author":"PS Group","year":"2002","unstructured":"Group PS. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens. 2002;20:729\u201337.","journal-title":"J Hypertens"},{"key":"116_CR39","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"FW Asselbergs","year":"2004","unstructured":"Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Prevention of R, Vascular Endstage Disease Intervention Trial I. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809\u201316.","journal-title":"Circulation"},{"key":"116_CR40","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1161\/CIRCULATIONAHA.107.723270","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Lin J, Solomon CG, Jablonski KA, Rice MM, Steffes M, et al. Prevention of Events With ACEII. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation. 2007;116:2687\u201393.","journal-title":"Circulation"},{"key":"116_CR41","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/hr.2013.63","volume":"36","author":"H Rakugi","year":"2013","unstructured":"Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res. 2013;36:947\u201358.","journal-title":"Hypertens Res"},{"key":"116_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","volume":"48","author":"K Norris","year":"2006","unstructured":"Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739\u201351.","journal-title":"Am J Kidney Dis"},{"key":"116_CR43","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","volume":"110","author":"MP Tokmakova","year":"2004","unstructured":"Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004;110:3667\u201373.","journal-title":"Circulation"},{"key":"116_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCULATIONAHA.105.592733","volume":"114","author":"SD Solomon","year":"2006","unstructured":"Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26\u201331.","journal-title":"Circulation"},{"key":"116_CR45","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1681\/ASN.2007020256","volume":"18","author":"V Perkovic","year":"2007","unstructured":"Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol. 2007;18:2766\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"116_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","volume":"167","author":"CB Bowling","year":"2013","unstructured":"Bowling CB, Sanders PW, Allman RM, Rogers WJ, Patel K, Aban IB, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. Int J Cardiol. 2013;167:151\u20136.","journal-title":"Int J Cardiol"},{"key":"116_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1291\/hypres.28.415","volume":"28","author":"T Nakamura","year":"2005","unstructured":"Nakamura T, Kanno Y, Takenaka T, Suzuki H. Efficacy of Candesartan on Outcome in Saitama Trial G. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res. 2005;28:415\u201323.","journal-title":"Hypertens Res"},{"key":"116_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","volume":"144","author":"M Rahman","year":"2006","unstructured":"Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172\u201380.","journal-title":"Ann Intern Med"},{"key":"116_CR49","first-page":"852","volume":"43","author":"G Bonner","year":"1993","unstructured":"Bonner G, Lederle RM, Scholze J, Stumpe KO. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy. Arzneimittelforschung. 1993;43:852\u20135.","journal-title":"Arzneimittelforschung"},{"key":"116_CR50","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/ndt\/13.12.3096","volume":"13","author":"H Holdaas","year":"1998","unstructured":"Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant. 1998;13:3096\u2013102.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR51","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S0895-7061(00)00287-9","volume":"13","author":"H Kumagai","year":"2000","unstructured":"Kumagai H, Hayashi K, Kumamaru H, Saruta T. Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens. 2000;13:980\u20135.","journal-title":"Am J Hypertens"},{"key":"116_CR52","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1093\/ndt\/16.11.2158","volume":"16","author":"H Herlitz","year":"2001","unstructured":"Herlitz H, Harris K, Risler T, Boner G, Bernheim J, Chanard J, et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant. 2001;16:2158\u201365.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR53","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","volume":"18","author":"HC Park","year":"2003","unstructured":"Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant. 2003;18:1115\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR54","first-page":"261","volume":"17","author":"L Vecchio Del","year":"2004","unstructured":"Del Vecchio L, Pozzi M, Salvetti A, Maschio G, Fusaroli M, Rovati C, et al. Manidipine Study G. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril. J Nephrol. 2004;17:261\u20139.","journal-title":"J Nephrol"},{"key":"116_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1291\/hypres.28.351","volume":"28","author":"T Ishimitsu","year":"2005","unstructured":"Ishimitsu T, Kobayashi T, Honda T, Takahashi M, Minami J, Ohta S, et al. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res. 2005;28:351\u20139.","journal-title":"Hypertens Res"},{"key":"116_CR56","first-page":"647","volume":"59","author":"T Peng","year":"2009","unstructured":"Peng T, Hu Z, Xia Q, Jiang B, Li X, Yang X. A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria. Arzneimittelforschung. 2009;59:647\u201350.","journal-title":"Arzneimittelforschung"},{"key":"116_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0272-6386(00)70195-8","volume":"35","author":"T Ecder","year":"2000","unstructured":"Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35:427\u201332.","journal-title":"Am J Kidney Dis"},{"key":"116_CR58","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrneph.2009.109","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol. 2009;5:436\u20137.","journal-title":"Nat Rev Nephrol"},{"key":"116_CR59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/j.ajkd.2015.03.030","volume":"66","author":"LA Inker","year":"2015","unstructured":"Inker LA, Okparavero A, Tighiouart H, Aspelund T, Andresdottir MB, Eiriksdottir G, et al. Midlife blood pressure and late-life GFR and albuminuria: an elderly general population cohort. Am J Kidney Dis. 2015;66:240\u20138.","journal-title":"Am J Kidney Dis"},{"key":"116_CR60","doi-asserted-by":"publisher","first-page":"5374746","DOI":"10.1155\/2016\/5374746","volume":"2016","author":"M Abe","year":"2016","unstructured":"Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M. Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. J Diabetes Res. 2016;2016:5374746.","journal-title":"J Diabetes Res"},{"key":"116_CR61","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/hr.2011.96","volume":"34","author":"M Nakayama","year":"2011","unstructured":"Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, et al. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. Hypertens Res. 2011;34:1106\u201310.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0116-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:19:31Z","timestamp":1684617571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0116-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["116"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0116-3","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}